The diminished exocytosis of agrin and LRP4 secretions at the neuromuscular junction has implications for associated Neuromuscular junction disease symptoms, similar to Myasthenia Gravis, observed in long term statin use.
In 1878, he described myasthenia gravis, a condition sometimes referred to as the "Erb-Goldflam disease" (named along with neurologist Samuel Goldflam).
Recently, PTPN22 has been associated with multiple autoimmune diseases including Type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, Hashimoto’s thyroiditis, Graves’ disease, Addison’s disease, Myasthenia Gravis, vitiligo, systemic sclerosis juvenile idiopathic arthritis, and psoriatic arthritis.
Tobinick has been issued patents for methods of perispinal administration, of certain recombinant DNA-derived (biologic) therapeutics including the TNF receptor fusion protein etanercept, for the treatment of certain neurologic disorders with widespread unmet medical need, including Alzheimer's disease; pain due to cancer metastasis to bone; severe, intractable, intervertebral disc-related pain and radiculopathy (including sciatica); and myasthenia gravis.